Published in Oncogene on October 07, 2004
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A (2006) 1.41
Genetic modeling of Li-Fraumeni syndrome in zebrafish. Dis Model Mech (2010) 0.95
Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome (2007) 0.94
Ubiquitination of human AP-endonuclease 1 (APE1) enhanced by T233E substitution and by CDK5. Nucleic Acids Res (2011) 0.82
The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12. Int J Biol Sci (2012) 0.76
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature (2009) 35.48
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell (2010) 12.27
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs. Dev Dyn (2007) 8.86
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature (2003) 6.01
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature (2009) 4.93
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc (2009) 4.50
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell (2009) 3.37
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Cancer modeling in the modern era: progress and challenges. Cell (2002) 3.12
Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature (2002) 3.05
Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature (2010) 3.03
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev (2013) 2.90
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol (2011) 2.72
Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem (2002) 2.68
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev (2011) 2.29
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A (2002) 2.24
Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell (2003) 2.23
Cell type-specific effects of Rb deletion in the murine retina. Genes Dev (2004) 2.18
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell (2013) 2.05
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell (2012) 2.04
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A (2010) 1.95
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol (2003) 1.93
Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci U S A (2005) 1.91
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A (2010) 1.86
The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem (2005) 1.85
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res (2009) 1.82
Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem (2002) 1.82
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev (2007) 1.81
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res (2007) 1.80
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol (2005) 1.79
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol (2006) 1.76
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76
Characterizing deformability and surface friction of cancer cells. Proc Natl Acad Sci U S A (2013) 1.72
Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 1.72
Progesterone receptor expression in neurofibromas. Cancer Res (2003) 1.72
Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res (2006) 1.69
Targeted deletion reveals an essential function for the telomere length regulator Trf1. Mol Cell Biol (2003) 1.69
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet (2003) 1.68
The Rb tumor suppressor is required for stress erythropoiesis. EMBO J (2004) 1.68
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A (2011) 1.68
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol (2015) 1.68
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67
Optimality in the development of intestinal crypts. Cell (2012) 1.67
A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep (2013) 1.67
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest (2007) 1.64
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev (2003) 1.64
An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell (2002) 1.63
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J (2004) 1.63